K-H Heider

646 total citations
9 papers, 532 citations indexed

About

K-H Heider is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, K-H Heider has authored 9 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Oncology. Recurrent topics in K-H Heider's work include Glycosylation and Glycoproteins Research (4 papers), Proteoglycans and glycosaminoglycans research (4 papers) and Peptidase Inhibition and Analysis (2 papers). K-H Heider is often cited by papers focused on Glycosylation and Glycoproteins Research (4 papers), Proteoglycans and glycosaminoglycans research (4 papers) and Peptidase Inhibition and Analysis (2 papers). K-H Heider collaborates with scholars based in Austria, Germany and Netherlands. K-H Heider's co-authors include Peter Herrlich, Helmut Ponta, Gϋnter von Minckwitz, M. Kaufmann, Hans‐Peter Sinn, Elínborg Ostermann, Paul L. Beaumier, Erik Patzelt, Horst Ahorn and Günther R. Adolf and has published in prestigious journals such as The Lancet, Gut and International Journal of Cancer.

In The Last Decade

K-H Heider

9 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K-H Heider Austria	8	331	278	199	123	81	9	532
Taher E.I. Taher Netherlands	8	307 0.9×	160 0.6×	141 0.7×	70 0.6×	116 1.4×	9	597
Suguru Hibino Japan	14	366 1.1×	165 0.6×	250 1.3×	110 0.9×	78 1.0×	21	594
Yasuyoshi Sohara Japan	10	243 0.7×	154 0.6×	171 0.9×	103 0.8×	46 0.6×	11	519
R. Arch Germany	5	274 0.8×	235 0.8×	119 0.6×	139 1.1×	94 1.2×	5	447
K C Gatter United Kingdom	6	330 1.0×	181 0.7×	131 0.7×	84 0.7×	41 0.5×	7	462
Luciano Zardi Italy	10	199 0.6×	180 0.6×	104 0.5×	303 2.5×	61 0.8×	10	554
Khashayar Lessan United Kingdom	6	216 0.7×	95 0.3×	118 0.6×	84 0.7×	73 0.9×	9	477
Motoshige Higashiyama Japan	9	263 0.8×	147 0.5×	204 1.0×	130 1.1×	31 0.4×	14	610
Kei Matsuda United States	7	478 1.4×	226 0.8×	305 1.5×	53 0.4×	59 0.7×	13	687
Ann Marie Grey United Kingdom	7	239 0.7×	159 0.6×	115 0.6×	81 0.7×	60 0.7×	8	460

Countries citing papers authored by K-H Heider

Since Specialization

Citations

This map shows the geographic impact of K-H Heider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K-H Heider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K-H Heider more than expected).

Fields of papers citing papers by K-H Heider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K-H Heider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K-H Heider. The network helps show where K-H Heider may publish in the future.

Co-authorship network of co-authors of K-H Heider

This figure shows the co-authorship network connecting the top 25 collaborators of K-H Heider. A scholar is included among the top collaborators of K-H Heider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K-H Heider. K-H Heider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Eksioglu, Erika A., X Chen, K-H Heider, et al.. (2017). Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 31(10). 2172–2180. 53 indexed citations

Dohnal, Alexander, et al.. (2002). Klade CS, Dohnal A, Furst W, Sommergruber W, Heider KH, Gharwan H, Ratschek M, Adolf GR. Identification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma. International Journal of Cancer 2002;97(2): 217–224.. International Journal of Cancer. 98(6). 956–956. 1 indexed citations

Dongen, Guus A.M.S. van, et al.. (1999). Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.. PubMed. 5(11). 3534–41. 26 indexed citations

Reinisch, Walter, K-H Heider, Georg Oberhuber, et al.. (1998). Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn’s disease. Gut. 43(3). 375–382. 11 indexed citations

Heider, K-H, Günther R. Adolf, Manfred Ratschek, & Kurt Zatloukal. (1996). Expression of CD44 isoforms in human renal cell carcinomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 428-428(4-5). 267–73. 20 indexed citations

Heider, K-H, et al.. (1996). Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunology Immunotherapy. 43(4). 245–253. 67 indexed citations

Kaufmann, M., Gϋnter von Minckwitz, K-H Heider, et al.. (1995). CD44 variant exon epitopes in primary breast cancer and length of survival. The Lancet. 345(8950). 615–619. 327 indexed citations

Otto, T., et al.. (1995). Prognostic factors for bladder cancer. Urological Research. 23(3). 137–141. 10 indexed citations

Pals, Steven T., Gerrit Koopman, K-H Heider, et al.. (1993). CD44 splice variants: expression during lymphocyte activation and tumor progression.. PubMed. 273–7. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact